Biogen Inc vs ING Groep NV — how do they compare? Biogen Inc trades at $203.5 (market cap $30.13B), while ING Groep NV trades at $35.49 (market cap $101.22B). The key difference: ING Groep NV is far larger — about 3.4× Biogen Inc's market cap, and ING Groep NV pays a 3.73% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | ING | |
|---|---|---|
Market Cap | $30.13B | $101.22B |
Sector | Health | Financials |
52-Week High | $216.63 | $35.92 |
52-Week Low | $128.93 | $23.66 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 3.73% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →